Saad Ragy, Markt Sarah C, Lillaney Prasheel, Profant Deb A, Fuller Douglas S, Poole Elizabeth M, Alvord Trevor, Prince Patricia, Desai Shaina, Whalen Marisa, Ni Weiyi, Black Jed
Jazz Pharmaceuticals, Palo Alto, CA, USA.
Jazz Pharmaceuticals, Philadelphia, PA, USA.
Nat Sci Sleep. 2025 Jul 30;17:1743-1755. doi: 10.2147/NSS.S498432. eCollection 2025.
Limited research describes the clinical and economic burden of idiopathic hypersomnia. This study compared this burden in individuals with idiopathic hypersomnia against matched controls.
This retrospective cohort study analyzed Merative™ MarketScan US claims (12/31/2013-2/29/2020). Individuals were ≥18 years of age and continuously enrolled during a 2-year assessment period. Individuals with idiopathic hypersomnia entered the cohort upon their first idiopathic hypersomnia medical claim; they were matched 1:5 with non-idiopathic hypersomnia controls on age, sex, region, insurance type, and cohort entry date. Odds of comorbid conditions experienced by individuals in either cohort during the 2-year assessment were compared. Healthcare resource utilization (HCRU) was presented as percentages by care setting. Median medical cost per patient per year (PPPY) was the sum of inpatient, outpatient, and emergency costs. -values were not adjusted for multiplicity.
This analysis included 11,412 individuals with idiopathic hypersomnia and 57,058 matched controls. In both cohorts, median age was 45 years and 65% of individuals were female. Compared with matched controls, individuals with idiopathic hypersomnia had 1.6- to 4.4-fold higher odds (all <0.0001) of grouped conditions defined by multilevel Clinical Classifications Software categories, from neoplasms to nervous systems diseases, including sleep-related conditions. Individuals with idiopathic hypersomnia had higher odds of all comorbid conditions evaluated, including sleep-related, cardiovascular and cardiometabolic, and neuropsychiatric conditions, compared with matched controls. Individuals with idiopathic hypersomnia had higher HCRU (outpatient, 100% vs 96.1%; emergency department, 46.6% vs 34.3%; inpatient, 10.2% vs 8.5%, all <0.0001) than matched controls. Median medical costs PPPY were higher for individuals with idiopathic hypersomnia ($4854) than matched controls ($1348).
Compared with matched controls, individuals with idiopathic hypersomnia had a higher clinical burden, spanning multiple organ systems, and a higher economic burden. Individuals' clinical profiles may be considered when treating idiopathic hypersomnia and providing holistic care.
关于特发性嗜睡症的临床和经济负担的研究有限。本研究比较了特发性嗜睡症患者与匹配对照组的这一负担。
这项回顾性队列研究分析了默克公司（Merative™）的美国市场扫描理赔数据（2013年12月31日至2020年2月29日）。研究对象年龄≥18岁，在为期2年的评估期内持续参保。特发性嗜睡症患者在首次提出特发性嗜睡症医疗理赔时进入队列；根据年龄、性别、地区、保险类型和队列入组日期，将他们与非特发性嗜睡症对照组按1:5的比例进行匹配。比较了两个队列中个体在2年评估期内出现合并症的几率。医疗资源利用情况（HCRU）按护理机构以百分比形式呈现。每位患者每年的医疗费用中位数（PPPY）是住院、门诊和急诊费用的总和。P值未针对多重性进行调整。
该分析纳入了11412例特发性嗜睡症患者和57058例匹配对照组。在两个队列中，年龄中位数均为45岁，65%的个体为女性。与匹配对照组相比，特发性嗜睡症患者出现由多级临床分类软件类别定义的分组疾病的几率高1.6至4.4倍（均<0.0001），这些疾病从肿瘤到神经系统疾病，包括与睡眠相关的疾病。与匹配对照组相比，特发性嗜睡症患者在所有评估的合并症中出现几率更高，包括与睡眠相关的、心血管和心脏代谢以及神经精神方面的疾病。特发性嗜睡症患者的医疗资源利用情况（门诊，100%对96.1%；急诊科，46.6%对34.3%；住院，10.2%对8.5%，均<0.0001）高于匹配对照组。特发性嗜睡症患者的每位患者每年医疗费用中位数（4854美元）高于匹配对照组（1348美元）。
与匹配对照组相比，特发性嗜睡症患者具有更高的临床负担，涉及多个器官系统，且经济负担更高。在治疗特发性嗜睡症和提供整体护理时，可考虑个体的临床特征。
